스크랩 원발성 액와 다한증 치료로서 폴리도카놀 주사에 대한 파일럿 연구

[땀족장(SWEATCHIEF)]

출처; https://www.ivysci.com/en/articles/7681980__A_Pilot_Study_on_Polidocanol_Injection_as_Treatment_for_Primary_Axillary_Hyperhidrosis

Avens Publishing Group Inviting Innovat J Clin Investigat Dermatol March 2020 Volume 8, Issue 1

© All rights are reserved by Calayan-Terte CMY, et al.

A Pilot Study on Polidocanol Injection as Treatment for Primary Axillary Hyperhidrosis

원발성 액와 다한증 치료로서 폴리도카놀 주사에 대한 파일럿 연구 

Keywords: Polidocanol; Axillary hyperhidrosis

키워드: 폴리도카놀; 액와 다한증

Abstract초록

Background: Hyperhidrosis is a condition marked by excessive sweating that can be debilitating leading to emotional and social embarrassment, as well as occupational, physical and psychological disability. Currently, treatment options available include pharmacologic and surgical. Pharmacologic treatments include topical aluminum salts, iontophoresis, systemic medications and botulinum toxin injection.

Meanwhile, surgical treatments include liposuction, direct excision of the glands, sympathectomy and laser treatment. The aforementioned treatments provide only temporary results, may have disabling side effects, may be expensive and some are more invasive that may lead to complications. There are a few studies regarding the use of sclerotherapy for chemical ablation of the sweat glands to treat axillary osmidrosis but, none yet for polidocanol and for axillary hyperhidrosis.

배경: 다한증은 과도한 발한으로 특징지어지는 질환으로, 정서적, 사회적 당혹감과 직업적, 신체적, 심리적 장애로 이어질 수 있는 쇠약해질 수 있습니다. 현재 이용 가능한 치료 옵션에는 약물적 및 수술적 치료가 있습니다. 약물적 치료에는 국소 알루미늄 염, 이온 도입법, 전신 약물 및 보툴리눔 독소 주사가 있습니다. 

한편, 수술적 치료에는 지방 흡입술, 샘 직접 절제, 교감신경 절제술 및 레이저 치료가 있습니다. 앞서 언급한 치료는 일시적인 결과만 제공하고, 장애를 유발하는 부작용이 있을 수 있으며, 비용이 많이 들 수 있으며, 일부는 합병증으로 이어질 수 있는 더 침습적입니다. 액와 오스미드로시스를 치료하기 위해 땀샘의 화학적 절제에 경화요법을 사용하는 것에 대한 연구는 몇 가지 있지만 폴리도카놀과 액와 과다한증에 대한 연구는 아직 없습니다.

Objective: The study aimed to determine the efficacy and safety of polidocanol injection as treatment for primary axillary hyperhidrosis.

목적: 이 연구는 원발성 액와 과다한증에 대한 치료로서 폴리도카놀 주사의 효능과 안전성을 확인하는 것을 목표로 했습니다.

Methods: Patients with primary axillary hyperhidrosis were enrolled. Identified hyperhidrotic areas were determined and injected with 1% polidocanol. The degree of hyperhidrosis was assessed using Hyperhidrosis Disease Severity Scale (HDSS), and Sweating Intensity Visual Scale (SIVS) at baseline, 2 and 4 weeks after injection.

방법: 원발성 액와 과다한증이 있는 환자를 등록했습니다. 확인된 과다한증 부위를 결정하고 1% 폴리도카놀을 주사했습니다. 과다한증의 정도는 주사 후 기준, 2주, 4주에 과다한증 질환 심각도 척도(HDSS)와 땀흘림 강도 시각 척도(SIVS)를 사용하여 평가했습니다.

Results: There was percentage reduction in sweating as reflected in the HDSS and SIVS scores pre-treatment and post treatment. The highest mean difference was noted between baseline and week 4. Results showed improvement of hyperhidrosis. However due to the limited number of patients, data was not all statistically significant. Patients reported slight discomfort after the procedure but it immediately waned. No other adverse events were noted.

결과: 치료 전과 치료 후 HDSS 및 SIVS 점수에 반영된 대로 땀흘림이 감소했습니다. 기준과 4주 사이에 가장 높은 평균 차이가 나타났습니다. 결과는 과다한증이 개선되었음을 보여주었습니다. 그러나 환자 수가 제한적이어서 모든 데이터가 통계적으로 유의미하지는 않았습니다. 환자들은 시술 후 약간의 불편함을 호소했지만 즉시 완화되었습니다. 다른 부작용은 발견되지 않았습니다.

Conclusion: Polidocanol 1% injection may be a promising treatment modality for primary axillary hyperhidrosis. It is effective and safe, and also inexpensive, less invasive and with minimal complications compared to ethanol and surgery.
결론: 폴리도카놀 1% 주사는 원발성 액와 다한증에 대한 유망한 치료 방법이 될 수 있습니다. 효과적이고 안전하며, 저렴하고, 에탄올과 수술에 비해 덜 침습적이며 합병증이 최소화됩니다.

[땀족장(SWEATCHIEF)]

세란통 스크랩